Skip to Content
scroll

Botanix Pharmaceuticals Ltd (BOT)

ASX.BOT $0.38

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

BOT $0.38

20 MINUTE DELAYED

TODAY

7.04 %

1 YEAR RETURN

0.00%

VOLUME

7,967,394

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.12

0.41

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

0.38

Change

0.03 (7.04)

Bid / Ask

0.38 - 0.38

Volume

7,967,394

Turnover

2,922,819

Open

0.37

Day Range

0.36 - 0.38

VWAP

0.37

Prev Close

0.36

Last Trade

24/07 3:32pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

2.00

Target Price

0.55

BUY

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.80

EBITDA

-11.70

Profit

-11.70

Earnings Per Share (EPS)

-0.01

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.55

Lt Growth Rate

0.00

Recommendation (BUY)

2.00
image description

Business Summary

Botanix Pharmaceuticals Limited is an Australia-based dermatology-focused company. The Company is engaged in the development of novel treatments for common skin diseases and infections. The Company has two development platforms, dermatology and antimicrobial products, both of which leverage the anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids. The Company’s product pipeline consists of Sofpironium Bromide, BTX 1503, BTX 1702, BTX 1204A, and BTX 1801. Sofpironium Bromide is an anticholinergic/antimuscarinic drug that blocks sweating at the gland by binding to the receptor and thereby blocking the sweat signal. Its BTX1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 is used for the treatment of papulopustular rosacea. Its BTX 1204A is used for Atopic Dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top